What question did this study set out to answer?

This research investigates sex-specific differences in disease burden among patients with ulcerative colitis treated with upadacitinib.

P0601Disease burden measured by the IBD-Disk shows sex-specific differences in Ulcerative Colitis and is reduced by upadacitinib – Interim results from the IBD-DACH Study EUROPE

View Full Paper

Ask AI

Bookmark

Authors

Interim results reveal sex-specific disease burden differences in ulcerative colitis, impacted by upadacitinib treatment.

This research investigates sex-specific differences in disease burden among patients with ulcerative colitis treated with upadacitinib.
Prospective multicenter study of upadacitinib in adult patients with moderate to severe UC.
Data collected on disease burden measured by the IBD-Disk across sexes.
Safety data analyzed for patients receiving upadacitinib.
Women showed significantly higher disease burden at baseline across all dimensions of the IBD-Disk.
Symptoms improved significantly for both sexes by week 8 and week 52, becoming comparable at week 52.
Higher rates of symptomatic remission were observed in both sexes, with women showing a greater initial improvement.

Wiestler et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark